Immunization against Viral Hepatitis B. Need for immunization against Viral Hepatitis
Conditions
Interventions
Intervention 1: Control Group: will recive one placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeaset-derived Hepatitis B vaccine intramuscular in left Deltoid muscle. I
Placebo
Treatment - Drugs
Control Group: will recive one placebo tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeaset-derived Hepatitis B vaccine intramuscular in left Deltoid muscle.
Intervention Group:will recive one 40 mg Atorvastatin tablet orally per day for 10 days and in 5th day 1 dose of recombinant yeaset-derived Hepatitis B vaccine intramuscular in left Deltoid muscle
Sponsors
Baqiyatallah University of Medical Sciences
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion criteria: HbsAb<10 after 3 dose hepatitis B vaccination- negative HBsAb- negative HBcAb- negative HBsAb. ?Exclusion criteria: positive serologic evidence of Hepatitis B infection- chronic use of Atorvastatin- immunosuppressive illness
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HBsAb level in serum. Timepoint: Before Atorvastatine use and 1 month after vaccination. Method of measurement: Quantitative ELIZA.;IL-4 , IL17 , TGFB , IFN-gamma. Timepoint: After WBC culture and exposure with vaccine in vitro. Method of measurement: Polymerase Chain Reaction (PCR). | — |
Secondary
| Measure | Time frame |
|---|---|
| Immunization against viral hepatitis B. Timepoint: Befor and 1 month after vaccination. Method of measurement: Quantitative ELIZA. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Nematollah Jonaidi Jafari
Baqiyatallah Medical Sciences University
Outcome results
None listed